Cargando…
Development of a glycoconjugate vaccine to prevent invasive Salmonella Typhimurium infections in sub-Saharan Africa
Invasive infections associated with non-typhoidal Salmonella (NTS) serovars Enteritidis (SE), Typhimurium (STm) and monophasic variant 1,4,[5],12:i:- are a major health problem in infants and young children in sub-Saharan Africa, and currently, there are no approved human NTS vaccines. NTS O-polysac...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5397072/ https://www.ncbi.nlm.nih.gov/pubmed/28388624 http://dx.doi.org/10.1371/journal.pntd.0005493 |
_version_ | 1783230199185276928 |
---|---|
author | Baliban, Scott M. Yang, Mingjun Ramachandran, Girish Curtis, Brittany Shridhar, Surekha Laufer, Rachel S. Wang, Jin Y. Van Druff, John Higginson, Ellen E. Hegerle, Nicolas Varney, Kristen M. Galen, James E. Tennant, Sharon M. Lees, Andrew MacKerell, Alexander D. Levine, Myron M. Simon, Raphael |
author_facet | Baliban, Scott M. Yang, Mingjun Ramachandran, Girish Curtis, Brittany Shridhar, Surekha Laufer, Rachel S. Wang, Jin Y. Van Druff, John Higginson, Ellen E. Hegerle, Nicolas Varney, Kristen M. Galen, James E. Tennant, Sharon M. Lees, Andrew MacKerell, Alexander D. Levine, Myron M. Simon, Raphael |
author_sort | Baliban, Scott M. |
collection | PubMed |
description | Invasive infections associated with non-typhoidal Salmonella (NTS) serovars Enteritidis (SE), Typhimurium (STm) and monophasic variant 1,4,[5],12:i:- are a major health problem in infants and young children in sub-Saharan Africa, and currently, there are no approved human NTS vaccines. NTS O-polysaccharides and flagellin proteins are protective antigens in animal models of invasive NTS infection. Conjugates of SE core and O-polysaccharide (COPS) chemically linked to SE flagellin have enhanced the anti-COPS immune response and protected mice against fatal challenge with a Malian SE blood isolate. We report herein the development of a STm glycoconjugate vaccine comprised of STm COPS conjugated to the homologous serovar phase 1 flagellin protein (FliC) with assessment of the role of COPS O-acetyls for functional immunity. Sun-type COPS conjugates linked through the polysaccharide reducing end to FliC were more immunogenic and protective in mice challenged with a Malian STm blood isolate than multipoint lattice conjugates (>95% vaccine efficacy [VE] versus 30–43% VE). Immunization with de-O-acetylated STm-COPS conjugated to CRM(197) provided significant but reduced protection against STm challenge compared to mice immunized with native STm-COPS:CRM(197) (63–74% VE versus 100% VE). Although OPS O-acetyls were highly immunogenic, post-vaccination sera that contained various O-acetyl epitope-specific antibody profiles displayed similar in vitro bactericidal activity when equivalent titers of anti-COPS IgG were assayed. In-silico molecular modeling further indicated that STm OPS forms a single dominant conformation, irrespective of O-acetylation, in which O-acetyls extend outward and are highly solvent exposed. These preclinical results establish important quality attributes for an STm vaccine that could be co-formulated with an SE-COPS:FliC glycoconjugate as a bivalent NTS vaccine for use in sub-Saharan Africa. |
format | Online Article Text |
id | pubmed-5397072 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-53970722017-05-15 Development of a glycoconjugate vaccine to prevent invasive Salmonella Typhimurium infections in sub-Saharan Africa Baliban, Scott M. Yang, Mingjun Ramachandran, Girish Curtis, Brittany Shridhar, Surekha Laufer, Rachel S. Wang, Jin Y. Van Druff, John Higginson, Ellen E. Hegerle, Nicolas Varney, Kristen M. Galen, James E. Tennant, Sharon M. Lees, Andrew MacKerell, Alexander D. Levine, Myron M. Simon, Raphael PLoS Negl Trop Dis Research Article Invasive infections associated with non-typhoidal Salmonella (NTS) serovars Enteritidis (SE), Typhimurium (STm) and monophasic variant 1,4,[5],12:i:- are a major health problem in infants and young children in sub-Saharan Africa, and currently, there are no approved human NTS vaccines. NTS O-polysaccharides and flagellin proteins are protective antigens in animal models of invasive NTS infection. Conjugates of SE core and O-polysaccharide (COPS) chemically linked to SE flagellin have enhanced the anti-COPS immune response and protected mice against fatal challenge with a Malian SE blood isolate. We report herein the development of a STm glycoconjugate vaccine comprised of STm COPS conjugated to the homologous serovar phase 1 flagellin protein (FliC) with assessment of the role of COPS O-acetyls for functional immunity. Sun-type COPS conjugates linked through the polysaccharide reducing end to FliC were more immunogenic and protective in mice challenged with a Malian STm blood isolate than multipoint lattice conjugates (>95% vaccine efficacy [VE] versus 30–43% VE). Immunization with de-O-acetylated STm-COPS conjugated to CRM(197) provided significant but reduced protection against STm challenge compared to mice immunized with native STm-COPS:CRM(197) (63–74% VE versus 100% VE). Although OPS O-acetyls were highly immunogenic, post-vaccination sera that contained various O-acetyl epitope-specific antibody profiles displayed similar in vitro bactericidal activity when equivalent titers of anti-COPS IgG were assayed. In-silico molecular modeling further indicated that STm OPS forms a single dominant conformation, irrespective of O-acetylation, in which O-acetyls extend outward and are highly solvent exposed. These preclinical results establish important quality attributes for an STm vaccine that could be co-formulated with an SE-COPS:FliC glycoconjugate as a bivalent NTS vaccine for use in sub-Saharan Africa. Public Library of Science 2017-04-07 /pmc/articles/PMC5397072/ /pubmed/28388624 http://dx.doi.org/10.1371/journal.pntd.0005493 Text en © 2017 Baliban et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Baliban, Scott M. Yang, Mingjun Ramachandran, Girish Curtis, Brittany Shridhar, Surekha Laufer, Rachel S. Wang, Jin Y. Van Druff, John Higginson, Ellen E. Hegerle, Nicolas Varney, Kristen M. Galen, James E. Tennant, Sharon M. Lees, Andrew MacKerell, Alexander D. Levine, Myron M. Simon, Raphael Development of a glycoconjugate vaccine to prevent invasive Salmonella Typhimurium infections in sub-Saharan Africa |
title | Development of a glycoconjugate vaccine to prevent invasive Salmonella Typhimurium infections in sub-Saharan Africa |
title_full | Development of a glycoconjugate vaccine to prevent invasive Salmonella Typhimurium infections in sub-Saharan Africa |
title_fullStr | Development of a glycoconjugate vaccine to prevent invasive Salmonella Typhimurium infections in sub-Saharan Africa |
title_full_unstemmed | Development of a glycoconjugate vaccine to prevent invasive Salmonella Typhimurium infections in sub-Saharan Africa |
title_short | Development of a glycoconjugate vaccine to prevent invasive Salmonella Typhimurium infections in sub-Saharan Africa |
title_sort | development of a glycoconjugate vaccine to prevent invasive salmonella typhimurium infections in sub-saharan africa |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5397072/ https://www.ncbi.nlm.nih.gov/pubmed/28388624 http://dx.doi.org/10.1371/journal.pntd.0005493 |
work_keys_str_mv | AT balibanscottm developmentofaglycoconjugatevaccinetopreventinvasivesalmonellatyphimuriuminfectionsinsubsaharanafrica AT yangmingjun developmentofaglycoconjugatevaccinetopreventinvasivesalmonellatyphimuriuminfectionsinsubsaharanafrica AT ramachandrangirish developmentofaglycoconjugatevaccinetopreventinvasivesalmonellatyphimuriuminfectionsinsubsaharanafrica AT curtisbrittany developmentofaglycoconjugatevaccinetopreventinvasivesalmonellatyphimuriuminfectionsinsubsaharanafrica AT shridharsurekha developmentofaglycoconjugatevaccinetopreventinvasivesalmonellatyphimuriuminfectionsinsubsaharanafrica AT lauferrachels developmentofaglycoconjugatevaccinetopreventinvasivesalmonellatyphimuriuminfectionsinsubsaharanafrica AT wangjiny developmentofaglycoconjugatevaccinetopreventinvasivesalmonellatyphimuriuminfectionsinsubsaharanafrica AT vandruffjohn developmentofaglycoconjugatevaccinetopreventinvasivesalmonellatyphimuriuminfectionsinsubsaharanafrica AT higginsonellene developmentofaglycoconjugatevaccinetopreventinvasivesalmonellatyphimuriuminfectionsinsubsaharanafrica AT hegerlenicolas developmentofaglycoconjugatevaccinetopreventinvasivesalmonellatyphimuriuminfectionsinsubsaharanafrica AT varneykristenm developmentofaglycoconjugatevaccinetopreventinvasivesalmonellatyphimuriuminfectionsinsubsaharanafrica AT galenjamese developmentofaglycoconjugatevaccinetopreventinvasivesalmonellatyphimuriuminfectionsinsubsaharanafrica AT tennantsharonm developmentofaglycoconjugatevaccinetopreventinvasivesalmonellatyphimuriuminfectionsinsubsaharanafrica AT leesandrew developmentofaglycoconjugatevaccinetopreventinvasivesalmonellatyphimuriuminfectionsinsubsaharanafrica AT mackerellalexanderd developmentofaglycoconjugatevaccinetopreventinvasivesalmonellatyphimuriuminfectionsinsubsaharanafrica AT levinemyronm developmentofaglycoconjugatevaccinetopreventinvasivesalmonellatyphimuriuminfectionsinsubsaharanafrica AT simonraphael developmentofaglycoconjugatevaccinetopreventinvasivesalmonellatyphimuriuminfectionsinsubsaharanafrica |